Story perspectives

FDA Boosts Scrutiny on Misleading Drug Ads Amid Criticism

9/16/2025

38 8

Summary

Story summary

FDA Commissioner Marty Makary criticized drugmakers and online pharmacies for misleading advertisements in an op-ed.
President Trump signed a memorandum to enhance drug risk information in ads, leading to stricter FDA regulations.
Makary noted a decline in enforcement actions and called for proactive monitoring of pharmaceutical advertising.
He specifically criticized Hims & Hers for a Super Bowl ad that omitted side effects of weight-loss medications.
The FDA will increase scrutiny on social media ads and online pharmacies to combat deceptive practices.

1 of 1

Story summary

FDA Commissioner Marty Makary criticized drugmakers and online pharmacies for misleading advertisements in an op-ed.
President Trump signed a memorandum to enhance drug risk information in ads, leading to stricter FDA regulations.
Makary noted a decline in enforcement actions and called for proactive monitoring of pharmaceutical advertising.
He specifically criticized Hims & Hers for a Super Bowl ad that omitted side effects of weight-loss medications.
The FDA will increase scrutiny on social media ads and online pharmacies to combat deceptive practices.